Which has the lower trailing P/E, BMRN or UHS?

UHS has the lower trailing P/E: BMRN trades at 144.67 and UHS at 7.23. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, BMRN or UHS?

Over the past five years, BMRN grew revenue faster — BMRN at a 12.19% CAGR versus UHS at 8.21%.

Does BMRN or UHS pay a bigger dividend?

UHS pays a dividend (0.45% yield), while BMRN has no payments in the available dividend history.

Is BMRN or UHS more profitable?

UHS runs the higher net margin — BMRN at 2.14% versus UHS at 8.42%.

How have BMRN and UHS total returns compared?

Over the past 10 years, BMRN delivered -4.98% and UHS delivered 4.35% annualized total return. Past performance doesn't predict future results.

BioMarin Pharmaceutical Inc. (BMRN) vs Universal Health Services, Inc. (UHS)

A side-by-side comparison of BioMarin Pharmaceutical Inc. and Universal Health Services, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

BMRN

BioMarin Pharmaceutical Inc.

$10.91B

$56.42HealthcareDelayed quote: Oct 6, 2026, 12:45 PM EDT

UHS

Universal Health Services, Inc.

$10.68B

$176.35HealthcareDelayed quote: Oct 6, 2026, 12:39 PM EDT

Total return — BMRN vs UHS

growth of $100 · dividends reinvested · last 10y

BMRN -39.5% (-4.9%/yr)UHS +51.9% (+4.3%/yr)UHS compounded faster over this window

BMRN UHS

BMRN vs UHS: by the numbers

•BMRN is the larger company ($10.91B vs $10.68B market cap).
•UHS trades at the lower trailing earnings multiple (7.23 vs 144.67 P/E), one valuation lens rather than an overall verdict.
•UHS converts more revenue to profit (8.42% vs 2.14% net margin).
•BMRN grew revenue faster over the past five years (12.19% vs 8.21% CAGR).
•UHS pays a dividend (0.45% yield), while BMRN has no payments in the available dividend history.

Metrics side by side

Valuation

Metric	BMRN	UHS
P/E ratio	144.67	7.23
Forward P/E	N/A	7.81
PEG ratio	N/A	0.45
P/S ratio	3.20	0.59
P/B ratio	1.73	1.42
EV / EBITDA	33.39	5.85
FCF yield	6.72%	7.74%

Profitability

Metric	BMRN	UHS
Gross margin	75.55%	90.69%
Operating margin	16.56%	11.36%
Net margin	2.14%	8.42%
ROE	1.15%	20.31%
ROIC	1.40%	11.74%

Dividends

Metric	BMRN	UHS
Dividend yield	N/A	0.45%
Payout ratio	N/A	3.28%

Growth (annualized)

Metric	BMRN	UHS
Revenue CAGR (5Y)	12.19%	8.21%
EPS CAGR (5Y)	-17.46%	16.19%
FCF CAGR (5Y)	33.84%	-12.18%
Total return CAGR (5Y)	-5.59%	6.18%

Frequently asked

Which has the lower trailing P/E, BMRN or UHS?: UHS has the lower trailing P/E: BMRN trades at 144.67 and UHS at 7.23. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, BMRN or UHS?: Over the past five years, BMRN grew revenue faster — BMRN at a 12.19% CAGR versus UHS at 8.21%.
Does BMRN or UHS pay a bigger dividend?: UHS pays a dividend (0.45% yield), while BMRN has no payments in the available dividend history.
Is BMRN or UHS more profitable?: UHS runs the higher net margin — BMRN at 2.14% versus UHS at 8.42%.
How have BMRN and UHS total returns compared?: Over the past 10 years, BMRN delivered -4.98% and UHS delivered 4.35% annualized total return. Past performance doesn't predict future results.

Go deeper

Full BMRN analysis Full UHS analysis Interactive comparison tool

Dig into the metrics

BioMarin Pharmaceutical P/E ratio Universal Health Services P/E ratio Universal Health Services dividend yield BioMarin Pharmaceutical ROE Universal Health Services ROE BioMarin Pharmaceutical operating margin Universal Health Services operating margin BioMarin Pharmaceutical revenue growth Universal Health Services revenue growth BioMarin Pharmaceutical free cash flow Universal Health Services free cash flow

BioMarin Pharmaceutical & Universal Health Services appear in these rankings

Highest FCF Yield Stocks Lowest P/E Ratio Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.